论文部分内容阅读
目的观察胰激肽原酶和莫沙比利联合治疗糖尿病胃轻瘫的疗效。方法72例糖尿病胃轻瘫(DGP)患者随机分为2组,治疗组36例口服莫沙比利联合胰激肽原酶肠溶片,对照组36例单用莫沙比利口服治疗,疗程为60d,观察治疗前后胃轻瘫症状改变及上消化道钡餐透视情况。结果治疗组显效率为47.2%,总有效率为88.9%,对照组显效率为27.8%,总有效率为66.7%。结论莫沙比利联合胰激肽原酶治疗糖尿病胃轻瘫优于单用莫沙比利,疗效显著,值得临床推广。
Objective To observe the therapeutic effect of pancreatic kallikrein combined with mosapride on diabetic gastroparesis. Methods Seventy-two patients with diabetic gastroparesis (DGP) were randomly divided into two groups. 36 patients in the treatment group were given mosapride and pancreatic kallikrein enteric-coated tablets, and 36 patients in the control group were treated with mosapride alone. The treatment course For 60d, observed before and after treatment of gastroparesis symptoms and upper gastrointestinal barium meal perspective. Results The effective rate of the treatment group was 47.2%, the total effective rate was 88.9%, the effective rate of the control group was 27.8%, the total effective rate was 66.7%. Conclusion Mosapride combined with pancreatic kallikrein is superior to mosapride alone in the treatment of diabetic gastroparesis. It is worthy of clinical promotion.